

Ademetionine in Obstructive Hypertrophic Cardiomyopathy

NCT07367724

| | |
|------------|---|
| Status | RECRUITING |
| Phase | Phase 2 |
| Sponsor | China National Center for Cardiovascular Diseases |
| Enrollment | 44 participants |

Key Eligibility Criteria

Inclusion (8)

- Meet the diagnostic criteria for HCM.
- Age \geq 18 years at screening.
- LVEF \geq 50% at screening.
- Echocardiography demonstrates a resting or provoked LVOTG \geq 30 mmHg at screening.
- NYHA Functional Class II-III at screening.
- ... and 3 more (see full listing online)

Exclusion (7)

- History of severe hypersensitivity to any component of Ademetionine 1,4-Butanedisulfonate Enteric-coated Tablets.
- History of psychiatric disorders, or current use of antidepressants such as clomipramine.
- Planned for any surgical (including septal reduction therapy) or interventional procedure during the trial period.
- Planned use of cardiac myosin inhibitors (e.g., Mavacamten) during the trial period.
- Currently pregnant or planning pregnancy.
- ... and 2 more (see full listing online)

Locations (3 total)

Fuwai Hospital, Beijing, China
Zhongshan Hospital, Shanghai Medical College of Fudan University, Shanghai, China
The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China